Volume 4 Supplement 1
Association for Immunotherapy of Cancer: Cancer Immunotherapy - 2nd Annual Meeting
Meeting abstracts
Association for Immunotherapy of Cancer: Cancer Immunotherapy - 2nd Annual Meeting. Go to conference site.
Mainz, Germany6-7 May 2004
Page 1 of 2
-
Citation: Cancer Cell International 2004 4(Suppl 1):S1
-
Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation
Citation: Cancer Cell International 2004 4(Suppl 1):S2 -
Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
Citation: Cancer Cell International 2004 4(Suppl 1):S3 -
HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy
Citation: Cancer Cell International 2004 4(Suppl 1):S4 -
Increased frequency of CTLA4+ TGFβ+ CD4+ CD25+ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma
Citation: Cancer Cell International 2004 4(Suppl 1):S5 -
MMP-7 inhibits CTL – tumor cell interaction
Citation: Cancer Cell International 2004 4(Suppl 1):S6 -
Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM
Citation: Cancer Cell International 2004 4(Suppl 1):S7 -
Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus
Citation: Cancer Cell International 2004 4(Suppl 1):S8 -
High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma
Citation: Cancer Cell International 2004 4(Suppl 1):S9 -
Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study
Citation: Cancer Cell International 2004 4(Suppl 1):S10 -
Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Citation: Cancer Cell International 2004 4(Suppl 1):S11 -
Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens
Citation: Cancer Cell International 2004 4(Suppl 1):S12 -
Therapeutic efficacy of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell clones in renal cell carcinoma
Citation: Cancer Cell International 2004 4(Suppl 1):S13 -
The role of glycosylation as a modulator for signalling strength in T cells
Citation: Cancer Cell International 2004 4(Suppl 1):S14 -
Migration of dendritic cells to regional lymph nodes in a vaccination trial
Citation: Cancer Cell International 2004 4(Suppl 1):S15 -
Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer
Citation: Cancer Cell International 2004 4(Suppl 1):S16 -
Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML
Citation: Cancer Cell International 2004 4(Suppl 1):S17 -
LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
Citation: Cancer Cell International 2004 4(Suppl 1):S18 -
Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing murine host
Citation: Cancer Cell International 2004 4(Suppl 1):S19 -
Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation™)
Citation: Cancer Cell International 2004 4(Suppl 1):S20 -
Proteasome inhibition enhances HLA-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma
Citation: Cancer Cell International 2004 4(Suppl 1):S21 -
Increased effector functions of a monoclonal antibody by glycoform engineering
Citation: Cancer Cell International 2004 4(Suppl 1):S22 -
Inhibition of signaling via erbB-receptors by antibodies that target the Lewis Y-antigen
Citation: Cancer Cell International 2004 4(Suppl 1):S23 -
Release of iC3b from apoptotic pancreatic tumor cells induces tolerance by binding to immature dendritic cells
Citation: Cancer Cell International 2004 4(Suppl 1):S24 -
Bisphosphonic acid acts as Gamma/Delta T cell activating antigen and has direct cytotoxic activity against pancreatic carcinoma cells
Citation: Cancer Cell International 2004 4(Suppl 1):S25 -
Regulation of p53 tumor specific immune responses in colorectal cancer patients
Citation: Cancer Cell International 2004 4(Suppl 1):S26 -
Assessment of genes associated with immune activation and regulation in pancreatic cancer patients
Citation: Cancer Cell International 2004 4(Suppl 1):S27 -
Modulation of tumour directed B cell responses by NK cells
Citation: Cancer Cell International 2004 4(Suppl 1):S28 -
NFκB activation and TGFβ loss signatures are prominent ex vivo responses of peripheral blood mononuclear cells
Citation: Cancer Cell International 2004 4(Suppl 1):S29 -
Enrichment of functional CD8 memory T cells specific for MUC1 in Bone Marrow of Multiple Myeloma Patients
Citation: Cancer Cell International 2004 4(Suppl 1):S30 -
Isolated γδ T cells express natural cytotoxicity receptors
Citation: Cancer Cell International 2004 4(Suppl 1):S31 -
The kinetics of accumulation of adoptively transferred ovalbumin-specific T cells in a transgenic, ovalbumin-expressing murine tumor
Citation: Cancer Cell International 2004 4(Suppl 1):S32 -
Tumor-specific murine T cell receptors displace endogenous TCRs in human T cells
Citation: Cancer Cell International 2004 4(Suppl 1):S33 -
Induction of leukemia reactive, allogeneic donor lymphocytes
Citation: Cancer Cell International 2004 4(Suppl 1):S34 -
Identification of a melanoma-associated chondroitin sulfate proteoglycan (MCSP) peptide recognized by CD4+ T lymphocytes on human melanoma cells
Citation: Cancer Cell International 2004 4(Suppl 1):S35 -
Chimeric carrier proteins for targeted delivery of tumor antigens to professional antigen presenting cells
Citation: Cancer Cell International 2004 4(Suppl 1):S36 -
Particulate antigenic structures: highly immunogenic carriers for T cell epitopes derived from tumour antigens
Citation: Cancer Cell International 2004 4(Suppl 1):S37 -
Development, monitoring and first immunological results of a phase I/II vaccination trial using genetically modified allogeneic breast cancer cells
Citation: Cancer Cell International 2004 4(Suppl 1):S38 -
Dendritic cell-based immunotherapy of hormone refractory prostate carcinoma (HRPCa) – a pilot trial
Citation: Cancer Cell International 2004 4(Suppl 1):S39 -
The European Searchable Tumour Cell and Databank, ESTDAB, as a tool for research in cancer immunology
Citation: Cancer Cell International 2004 4(Suppl 1):S40 -
Efficient in vitro expression of human reverse transcriptase (hTERT) in dendritic cells of lung cancer patients using RNA electrotransfection
Citation: Cancer Cell International 2004 4(Suppl 1):S41 -
Parvovirus H1-induced tumor cell death enhances human immune response via crosspresentation of dendritic cells
Citation: Cancer Cell International 2004 4(Suppl 1):S42 -
Optimizing the antigen loading of dendritic cells with exogenous peptides
Citation: Cancer Cell International 2004 4(Suppl 1):S43 -
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
Citation: Cancer Cell International 2004 4(Suppl 1):S44 -
Survival and homing of ex vivo expanded donor derived dendritic cells after allogeneic BMT
Citation: Cancer Cell International 2004 4(Suppl 1):S45 -
PBMCs transfected with RNActive stimulate specific T-cells
Citation: Cancer Cell International 2004 4(Suppl 1):S46 -
Addition of histamine to IL-2 treatment augments T1 cell-function in melanoma patients in vivo: results from a randomized clinical trial of IL-2 with or without histamine (MP 104)
Citation: Cancer Cell International 2004 4(Suppl 1):S47 -
Peptide vaccination induces specific effector and memory T cells but fails to enhance preexisting T cell immunity
Citation: Cancer Cell International 2004 4(Suppl 1):S48 -
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
Citation: Cancer Cell International 2004 4(Suppl 1):S49 -
Identification of a novel epitope derived from the cancer-germline antigen, HAGE, displaying both in-vitro and in-vivo immunogenicity
Citation: Cancer Cell International 2004 4(Suppl 1):S50
Follow
Annual Journal Metrics
-
2022 Citation Impact
5.8 - 2-year Impact Factor
5.6 - 5-year Impact Factor
0.994 - SNIP (Source Normalized Impact per Paper)
1.145 - SJR (SCImago Journal Rank)2022 Speed
10 days submission to first editorial decision for all manuscripts (Median)
116 days submission to accept (Median)2022 Usage
2,208,493 downloads
1,520 Altmetric mentions
On the blog
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
-
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).